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Introduction
Type 1 diabetes mellitus (T1DM) is a chronic disorder
with well-known short- and long-term consequences (1).
One of the long-term consequences is severe impairment of
growth and development, the so-called Mauriac syndrome
(2). As a result of the major advances in diabetes care, this
entity has now become a rarity. Indeed, during the last 
decade, there are some studies reporting positive growth
characteristics in diabetic children (3,4). However, growth
deceleration during the course of the disease has been 
reported in various countries around the world, such as 
Austria, Brazil, Czech Republic, Germany, and Sudan (5-8).
The extent of the impact of clinical and laboratory variables
on the growth of children with T1DM is also a controversial
issue. 
In this study, we aimed to evaluate the effect of T1DM
on growth and body mass index (BMI) in children followed
in the Department of Pediatric Endocrinology at Dokuz Eylul
University. 
Methods
Setting and Subjects
This study was conducted in the Department of 
Pediatric Endocrinology, Dokuz Eylul University, Izmir, 
Turkey. The hospital is one of the two tertiary referral 
university centers in the Aegean region of Turkey. The 
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Objective: To retrospectively evaluate the effect of type 1 diabetes on
growth.
Methods: Patients with Type 1 diabetes mellitus (T1DM) followed for
at least one year after diagnosis, and without coexisting disorder that
could affect growth, were included in this retrospective analysis. Height
and body mass index (BMI) values were recorded. According to the data
obtained at the end of each year of disease, the patients were divided
into two groups: Group 1 (patients whose height standard deviation
score (SDS) did not change or showed improvement) and Group 2
(patients whose height SDS showed a decline). The two groups were
compared with respect to clinical and laboratory variables.
Results:Among the 248 patients followed, 101 (M/F:55/46) fulfilled the
inclusion criteria. Overall, the mean height SDS of the patients did not
change significantly during the follow-up period. BMI SDS showed no
change during the course of the disease, except for a significant rise
observed at the end of the first year compared to the value at diagnosis.
Height SDS of the patients in Group 1 was higher compared to those in
Group 2 from the 2nd year of disease onwards (2nd year, p=0.03; 3rd year,
p=0.02; 4th year, p=0.01; 5th year, p=0.03). The ratio of patients 
presenting with diabetic ketoacidosis at onset was significantly higher
in Group 1 at the 4th year of diagnosis (p=0.03). Additionally, the mean
HbA1c level showed a modest negative correlation with Δ height SDS
at the 3rd year of diagnosis (r=-0.3, p=0.03).
Conclusions: No significant deteriorative effect of T1DM on auxological
parameters was observed at short term. Some clinical and laboratory
variables related with metabolic control were found to correlate with
growth.
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A total of 248 patients with T1DM have been followed since
the establishment of our department in 1990. The subjects
that fulfilled the following inclusion criteria were enrolled in
the study: (1) being diagnosed in our center, (2) a follow-up 
duration of at least 1 year, (3) not having achieved near-final
height at presentation and (4) absence of coexisting 
disorder, such as celiac disease, autoimmune thyroiditis,
that could affect growth. The study consisted of 101 
patients (55 males, 46 females; 17 diagnosed between
1992 and 2000, 84 diagnosed between 2000 and 2007).
Clinical and Laboratory Evaluation
In general, diabetic children are followed at 3-month 
intervals in our Department. At each clinic visit, the 
following assessments are performed: complete physical
examination, evaluation of capillary blood glucose 
measurements done at home, blood and urine sampling,
and improvement in diabetes knowledge by a team 
consisting of a pediatric endocrinologist, a diabetes nurse,
and a diabetes dietitian. 
A Harpenden fixed stadiometer was used to measure
the standing height (cm) to the nearest 0.1 cm. Body 
weight (kg) measurements were performed with a SECA
scale sensitive to 0.1 kg, with subjects dressed in a light 
T-shirt and shorts. BMI was calculated as weight (kg) 
divided by the square of height (m). Auxological data were
converted to standard deviation scores (SDS) using data from
the National Health and Nutrition Examination Survey (9). The
heights of the parents were either measured or 
recorded via telephone contact. The target height was 
computed as mean parental height in centimeters, +6.5 cm
for boys and -6.5 cm for girls. 
In our clinic, the tests for HbA1c and urine analyses are
obtained every three months. Unless clinically indicated, 
routine analyses for complete blood count, liver and kidney
function tests, lipid profiles, thyroid function tests, and 
celiac antibodies are made annually. Presence of microvascular
complications (24-hour microalbumin excretion, eye 
fundoscopy, and electromyography) is also assessed 
regularly. HbA1c values were determined by Abbott 
Architect ci8200 system. HbA1c values between 4.5-6%
were defined as normal.
Analysis 
The patients meeting the inclusion criteria were evaluated
with regard to mean height and BMI SDS at the end of each
year of disease only during the first five years of follow-up,
since the number of attending patients decreased in 
subsequent years. Thus, according to the data obtained at
the end of each year of disease in the first five years of 
follow-up, the patients were grouped as: those whose 
height SDS did not change or improved since diagnosis
(Group 1) and those who showed a deterioration in their
height SDS since diagnosis (Group 2). These groups were
compared regarding gender, age at diagnosis, height SDS,
Δ height SDS (current height SDS – height SDS at 
presentation), target height SDS, BMI SDS, Δ BMI SDS
(current BMI SDS-BMI SDS at presentation), pubertal state,
clinical picture at presentation, and also regarding dominant
mode of therapy, mean daily insulin dose, mean basal/total
daily insulin ratio, and mean HbA1c level since the onset of
the disease. Correlations of Δ height SDS at the end of each
year of disease with Δ BMI SDS and long-term values of 
insulin dose, basal/total daily insulin ratio, and HbA1c levels
were also assessed.
Statistical Evaluation
The data were statistically analyzed using computer
software SPSS 11.0 (Chicago, IL, USA). All analyses were
performed after ascertaining that the data were normally
distributed using the one-sample Kolmogorov-Smirnov test.
The group means and standard deviations were determined
using descriptive statistics. Paired-samples t-test and 
repeated measures ANOVA test were used to assess the
course of auxological variables. Group 1 and 2 were compared
regarding the influence of the above-mentioned clinical and
laboratory variables using Student’s t and chi-square tests.
Univariate correlation analysis included all patients and was
performed using Pearson’s test to identify the degree 
of correlation of numerical variables with Δ height SDS. 
A p-value of <0.05 was chosen to represent statistical 
significance. 
Results
The mean age at diagnosis was 8.9±3.5 years (range, 
2-15.5 years) and the mean duration of follow-up was
4.1±2.5 years (range, 1-13 years). Mean and standard 
deviation values for height and BMI SDS at diagnosis and
during the follow-up period are presented in Table 1. The
mean values for auxological variables at the time of 
diagnosis of the 101 patients (M/F:55/46) were as follows:
height SDS 0.3±1.1, BMI SDS -0.6±1.4. At the time of 
diagnosis, both sexes were found to be taller compared to
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SDS -0.16±0.8 vs. height SDS at diagnosis 0.35±1.1,
p=0.001 and females (n=42), target height SDS -0.24±0.8
vs. height SDS at diagnosis 0.04±0.8, p=0.04]. 
Table 2 presents the results of comparisons performed
for various follow-up durations. The mean height SDS of the
patients did not change significantly in any of the follow-up
durations. All comparisons between BMI SDS values at the
start and at the end of separate follow-up periods showed
significant differences. In fact, these differences resulted
solely from regaining the weight, which was lost during the
onset of disease, especially during the first year.
There was no significant change in the mean values of
height SDS during the first 5 years of the disease; however,
comparisons between Groups 1 and 2 revealed significant
differences in height SDS values from the 2nd year of 
disease onwards (p=0.03, p=0.02, p=0.01, p=0.03, 
respectively) (Table 3). Presenting with diabetic ketoacidosis
(DKA) at the onset was significantly associated with 
maintaining or gaining height SDS by the 4th year of 
diagnosis (p=0.03). On the other hand, the mean HbA1c 
level showed modest negative correlation with Δ height
SDS at the 3rd year of follow-up (r=-0.3, p=0.03). Remaining
comparisons between the groups (mean target height SDS,
rate of pubertal patients, mean daily insulin dose, mean 
basal/total insulin ratio, and mean HbA1c) or correlation
analyses including the whole study group revealed no other
significant association with Δ height SDS.
Discussion
At the time of diagnosis, our patients (both males and
females) were significantly taller compared to their genetic
target heights and slightly taller compared to reference 
values. It was first noted in the 1920’s that diabetic children
have a tendency to be “over-height” on admission 
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Table 1. Mean values for auxological variables at diagnosis and during follow-up in T1DM* patients
Height SDS BMI SDS
Male (n=55) Female (n=46) Male (n=55) Female (n=46)
n Mean±SD n Mean±SD n Mean±SD n Mean±SD
Diagnosis 55 0.3±1.1 46 0.1±0.9 55 -0.6±1.4 46 -0.5±1.6
1st year follow-up 54 0.3±1 45 0.2±0.9 54 0.1±0.9 45 0.2±0.9
2nd year follow-up 49 0.3±1.1 33 0.0±0.8 49 0.1±0.9 33 0.2±0.8
3rd year follow-up 30 0.3±1.1 23 -0.2±0.8 30 0.0±0.9 23 0.3±0.9
4th year follow-up 23 0.3±1.2 19 -0.3±0.9 23 -0.2±0.9 19 0.5±0.7
5th year follow-up  19 0.1±1 14 -0.3±0.9 19 0.0±0.9 14 0.4±0.8
*T1DM: type 1 diabetes mellitus
Table 2. Results of the statistical analyses* in height and BMI SDS in T1DM patients at different follow-up years
Height SDS BMI SDS
At the end of  At the end of the 
Sex (n) At diagnosis follow-up period P At diagnosis follow-up period  p
1 year€ M (54) 0.3±1.1 0.3±1 NS -0.5±1.3 0.1±0.9 0.001
F (45) 0.1±0.9 0.2±0.9 NS -0.3±1.1 0.2±0.9 0.001
2 years¥ M (49) 0.3±1.1 0.3±1.2 NS -0.6±1.4 0.1±0.9 0.001
F (33) -0.1±0.7 0±0.8 NS -0.4±1.1 0.2±0.8 0.01
3 years¥ M (30) 0.3±1 0.4±1.1 NS -0.6±1.3 0±0.9 0.005
F (22) -0.2±0.8 -0.2±0.8 NS -0.6±1 0.4±0.8 0.01
4 years¥ M (22) 0.3±0.9 0.3±1.2 NS -0.8±1.1 -0.2±0.9 0.02
F (19) -0.4±0.8 -0.3±0.9 NS -0.6±1.1 0.5±0.7 0.001
5 years¥ M (16) 0.2±1 0±1 NS -0.7±1.2 0±1 0.02
F (14) -0.4±0.7 -0.3±0.9 NS -0.5±1.1 0.5±0.8 0.02
€Paired-samples t-test, ¥Repeated Measures ANOVA, M: male, F: female, NS: nonsignificant75
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xcompared to normal children (10). In later years, conflicting
results have been reported in over 30 studies on growth of
children with T1DM. In 2002, DiLiberti et al (11) assessed
the relevant data in a meta-analysis and concluded that the
diabetic children were taller at the time of diagnosis 
attributing this finding to the taller parental stature. Our 
results, similar to the results of other studies, revealed that
diabetic children were taller when compared to their 
midparental height SDS (8,12,13). Secular trend toward 
increased height might account for this difference (14). 
Recently, Larsson et al (15) demonstrated that a high human
leukocyte antigen (HLA) risk for diabetes was correlated to
an increased birth length SDS in children who later developed
diabetes. However, this finding could not explain the increased
postnatal height development of these children.
Studies evaluating the course of auxological variables
following the diagnosis of T1DM generally report deterioration
in height SDS. These early studies were conducted on 
children who were receiving conventional insulin treatment.
However, Poyrazoglu et al (17) reported that final heights of
the diabetic children followed between 1970 and 1987 were
consistent with their target heights and no significant 
overall height loss was observed. Since early 1990’s, our
understanding and the quality of management of T1DM 
have enormously improved (4,5,7,8,13,16). In this study,
we were able to evaluate the course of height SDS only in
the first 5 years of follow-up and found that no significant
change in height SDS occurred in both sexes. Bognetti et al (16)
found that height SDS significantly decreased even in the
first 3 years of disease in children and adolescents diagnosed
between 1989 and 1992. Similarly, Donaghue et al (4) found
loss of height SDS by the 5th year of disease in T1DM patients
diagnosed between 1974 and 1991. However, similar to our
findings, the 5th year height SDS of their patients diagnosed
between 1991 and 1995 were similar to height SDS values
at the time of diagnosis.
While the mean height SDS did not change during the
first 5 years in our patients, we observed that some 
diabetic children maintained or gained (Group 1), while 
some diabetics lost height SDS (Group 2). Analyses comparing
these children revealed two significant associations. First,
presenting with DKA, which might have caused the patient
and his/her family to be more conscientious, was more
common in Group 1 by the 4th year of disease. Second,
long-term mean HbA1c level had modest negative 
correlation with Δ height SDS by the 3rd year of disease. 
Similar intra-group comparison was made by Danne (18),
but at the age of 18. They found that longer diabetes 
duration, higher long-term mean HbA1c, and higher BMI at
the age of 18 were significantly associated with a change in
height SDS more than-1, compared to those who gained
height SDS since diagnosis. However, we did not find any
significant factors, other than the above-mentioned 
variables. Our inability to demonstrate any other statistically
significant associations might be due to the decreasing
number of patients, limiting the power of the statistical
analysis. For instance, from the 3rd year of disease 
onwards, noticeably higher percentage of patients in Group
1 were using multiple daily insulin injection or pump therapy
compared to Group 2. On the other hand, there may be 
other uncovered factors for deterioration of height SDS,
such as the effect of variations in blood glucose, which was
shown to cause oxidative stress and epigenetic deteriorati-
ve changes, without affecting HbA1c levels (19-21).
In conclusion, no significant deteriorative effect of
T1DM on auxological parameters in short term was 
observed in our patients. However, some clinical and 
laboratory variables related with metabolic control were 
found to correlate with growth.
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